<DOC>
	<DOCNO>NCT01208285</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics safety single dose VX-770 subject moderate hepatic impairment .</brief_summary>
	<brief_title>Study VX-770 Subjects With Moderate Hepatic Impairment Matched Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Group A ( Subjects Hepatic Impairment ) : male female 18 65 year age subject must ChildPugh total score 7 9 subject must agree use 1 highly effective method contraception study 90 day completion study subject must body mass index ( BMI ) 18 35 kg/m2 Group B ( Healthy Subjects ) : male female 18 65 year age subject match subject hepatic impairment sex , BMI , cigarette smoking habit , age subject must agree use 1 highly effective method contraception study 90 day completion study Group A ( Subjects Hepatic Impairment ) : subject clinically stable history illness , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer study drug ( ) subject subject unwilling unable discontinue use inhibitor inducer CYP3A subject history alcohol abuse within 1 year illicit drug abuse within 2 year subject smoke 10 cigarette per day subject fluctuate rapidly deteriorate hepatic function subject significant renal dysfunction subject HIV , active hepatitis B subject previous solid organ bone marrow transplantation Group B ( Healthy Subjects ) : subject history illness , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer study drug ( ) subject subject unwilling unable discontinue use inhibitor inducer CYP3A subject history alcohol illicit drug abuse within 2 year subject smoke 10 cigarette per day subject HIV , hepatitis C , active hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>